Abstract
Pulmonary arterial hypertension is a serious disease with significant morbidity and mortality. Although it can occur idiopathically, it is more commonly associated with other cardiac or lung diseases. While most of the available therapies have been tested in adult populations and most therapies in children remain off-label, new reports and randomized trials are emerging that inform the treatment of pediatric populations. This review discusses currently available therapies for pediatric pulmonary hypertension, their biological rationales, and evidence for their clinical effectiveness.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1130-1146 |
| Number of pages | 17 |
| Journal | Pediatric Clinics of North America |
| Volume | 59 |
| Issue number | 5 |
| DOIs | |
| State | Published - Oct 2012 |
| Externally published | Yes |
Keywords
- Endothelin
- Nitric oxide
- Phosphodiesterase
- Prostacyclin
- Pulmonary hypertension
- Pulmonary vasculature
- Vasodilator
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health
Fingerprint Dive into the research topics of 'Pharmacotherapy for Pulmonary Hypertension'. Together they form a unique fingerprint.
Cite this
Steinhorn, R. H. (2012). Pharmacotherapy for Pulmonary Hypertension. Pediatric Clinics of North America, 59(5), 1130-1146. https://doi.org/10.1016/j.pcl.2012.07.011